{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T23:24:33Z","timestamp":1768087473587,"version":"3.49.0"},"reference-count":34,"publisher":"BMJ","issue":"12","license":[{"start":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T00:00:00Z","timestamp":1701993600000},"content-version":"unspecified","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2023,11,25]]},"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To use a nomogram to predict the risk of mortality and estimate the impact of current treatment on the prognosis of glioma patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 3798 cases were obtained from the Surveillance Epidemiology and End Results database according to the selection criteria. A nomogram was built on the independent clinical factors screened by the variance inflation factor, univariate analyses and a multivariate Cox regression model. Then, categorising the overall population into high-risk, medium-risk and low-risk groups using nomogram-derived risk scores, to study the impact of treatment on different subgroups\u2019 survival outcomes. Furthermore, based on the postmatch cohorts, the influences of treatment on survival outcomes were assessed by the log-rank test.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Result<\/jats:title>\n                    <jats:p>Age, race, stage of disease, histological type, histological grade, surgery, radiotherapy and chemotherapy were identified as the independent prognostic factors. A nomogram with good discrimination and consistency was built. Generally, the patients who underwent surgery, radiotherapy and chemotherapy were more likely to achieve better prognosis than those who did not, except for those who received radiotherapy in the low-risk cohort and those who underwent surgery in the high-risk cohort. Furthermore, the isocitrate dehydrogenase 1\/2 (IDH1\/2) wild-type patients with surgery, radiotherapy or chemotherapy tended to have higher survival probabilities, while some inconsistent results were observed in the IDH mutant-type cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Surgery, radiotherapy and chemotherapy improved the prognosis, while appropriate selection of topical treatment for the low-risk or high-risk patients deserves further consideration. IDH status gene might be a reliable indicator of therapeutic effectiveness.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2023-079341","type":"journal-article","created":{"date-parts":[[2023,12,9]],"date-time":"2023-12-09T13:23:43Z","timestamp":1702128223000},"page":"e079341","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Risk prediction and treatment assessment in glioma patients using SEER database: a prospective observational study"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3188-2929","authenticated-orcid":false,"given":"XinRong","family":"Li","sequence":"first","affiliation":[{"name":"Department of Integrative Medicine and Medical Oncology, Shengzhou People's Hospital (the First Affiliated Hospital of Zhejiang University Shengzhou Branch), Shengzhou, Zhejiang, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Shao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shengzhou People's Hospital (the First Affiliated Hospital of Zhejiang University Shengzhou Branch), Shengzhou, Zhejiang, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ZeMing","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Integrative Medicine and Medical Oncology, Shengzhou People's Hospital (the First Affiliated Hospital of Zhejiang University Shengzhou Branch), Shengzhou, Zhejiang, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JunQuan","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Integrative Medicine and Medical Oncology, Shengzhou People's Hospital (the First Affiliated Hospital of Zhejiang University Shengzhou Branch), Shengzhou, Zhejiang, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2023,12,9]]},"reference":[{"key":"2025121400223048000_13.12.e079341.1","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/neuonc\/noy131","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2011-2015","volume":"20","author":"Ostrom","year":"2018","journal-title":"Neuro Oncol"},{"key":"2025121400223048000_13.12.e079341.2","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s11060-016-2288-5","article-title":"NRG oncology RTOG 0625: a randomized phase II trial of bevacizumab with either Irinotecan or dose-dense temozolomide in recurrent glioblastoma","volume":"131","author":"Gilbert","year":"2017","journal-title":"J Neurooncol"},{"key":"2025121400223048000_13.12.e079341.3","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41591-018-0337-7","article-title":"Neoadjuvant anti-PD-1 Immunotherapy promotes a survival benefit with Intratumoral and systemic immune responses in recurrent glioblastoma","volume":"25","author":"Cloughesy","year":"2019","journal-title":"Nat Med"},{"key":"2025121400223048000_13.12.e079341.4","doi-asserted-by":"crossref","DOI":"10.3390\/toxins14030170","article-title":"Expression of the first recombinant anti-tumoral snake venom kunitz-type serine protease inhibitor","volume":"14","author":"Morjen","year":"2022","journal-title":"Toxins"},{"key":"2025121400223048000_13.12.e079341.5","first-page":"344","article-title":"Vaccine for IDH mutant glioma","volume":"20","author":"Crunkhorn","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"2025121400223048000_13.12.e079341.6","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/neuonc\/noz150","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012-2016","volume":"21","author":"Ostrom","year":"2019","journal-title":"Neuro Oncol"},{"key":"2025121400223048000_13.12.e079341.7","doi-asserted-by":"publisher","DOI":"10.3171\/2013.9.JNS13877"},{"key":"2025121400223048000_13.12.e079341.8","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-021-08105-y","article-title":"Comparing the characteristics and predicting the survival of patients with head and neck melanoma versus body melanoma: a population-based study","volume":"21","author":"Ding","year":"2021","journal-title":"BMC Cancer"},{"key":"2025121400223048000_13.12.e079341.9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0092585","article-title":"No survival improvement for patients with angioimmunoblastic T-cell lymphoma over the past two decades: a population-based study of 1207 cases","volume":"9","author":"Xu","year":"2014","journal-title":"PLoS ONE"},{"key":"2025121400223048000_13.12.e079341.10","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1200\/JCO.2017.75.3228","article-title":"Radiofrequency ablation versus stereotactic body radiotherapy for localized hepatocellular carcinoma in nonsurgically managed patients: analysis of the National cancer database","volume":"36","author":"Rajyaguru","year":"2018","journal-title":"J Clin Oncol"},{"key":"2025121400223048000_13.12.e079341.11","doi-asserted-by":"crossref","first-page":"15017","DOI":"10.1038\/nrdp.2015.17","article-title":"Glioma","volume":"1","author":"Weller","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"2025121400223048000_13.12.e079341.12","doi-asserted-by":"publisher","DOI":"10.1017\/pan.2019.11"},{"key":"2025121400223048000_13.12.e079341.13","doi-asserted-by":"crossref","first-page":"603","DOI":"10.2217\/cer-2020-0013","article-title":"Propensity score matching and inverse probability of treatment weighting to address confounding by indication in comparative effectiveness research of oral anticoagulants","volume":"9","author":"Allan","year":"2020","journal-title":"J Comp Eff Res"},{"key":"2025121400223048000_13.12.e079341.14","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/ane.12973","article-title":"Age and surgical outcome of low-grade glioma in Sweden","volume":"138","author":"Corell","year":"2018","journal-title":"Acta Neurol Scand"},{"key":"2025121400223048000_13.12.e079341.15","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.7150\/jca.41123","article-title":"Prognostic significance of age related genes in patients with lower grade glioma","volume":"11","author":"Wang","year":"2020","journal-title":"J Cancer"},{"key":"2025121400223048000_13.12.e079341.16","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.clon.2014.11.026","article-title":"Survival outcomes in elderly patients with glioblastoma","volume":"27","author":"Tsang","year":"2015","journal-title":"Clin Oncol"},{"key":"2025121400223048000_13.12.e079341.17","first-page":"173","article-title":"Glioblastoma in the elderly","volume":"17","author":"Laigle-Donadey","year":"2019","journal-title":"Geriatr Psychol Neuropsychiatr Vieil"},{"key":"2025121400223048000_13.12.e079341.18","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s11060-017-2439-3","article-title":"Patterns of care and treatment outcomes in older adults with low grade glioma: a 50-year experience","volume":"133","author":"Youland","year":"2017","journal-title":"J Neurooncol"},{"key":"2025121400223048000_13.12.e079341.19","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1001\/jamaoncol.2018.1789","article-title":"Adult glioma incidence and survival by race or Ethnicity in the United States from 2000 to 2014","volume":"4","author":"Ostrom","year":"2018","journal-title":"JAMA Oncol"},{"key":"2025121400223048000_13.12.e079341.20","doi-asserted-by":"publisher","DOI":"10.1126\/science.1164382"},{"key":"2025121400223048000_13.12.e079341.21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402121"},{"key":"2025121400223048000_13.12.e079341.22","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.3171\/2021.5.JNS21310","article-title":"5-Aminolevulinic acid for enhanced surgical visualization of high-grade gliomas: a prospective, multicenter study","volume":"136","author":"Schupper","year":"2022","journal-title":"J Neurosurg"},{"key":"2025121400223048000_13.12.e079341.23","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0095-6"},{"key":"2025121400223048000_13.12.e079341.24","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s10014-018-0312-5","article-title":"Immunohistochemical ATRX expression is not a surrogate for 1P19Q codeletion","volume":"35","author":"Yamamichi","year":"2018","journal-title":"Brain Tumor Pathol"},{"key":"2025121400223048000_13.12.e079341.25","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-016-1545-1"},{"key":"2025121400223048000_13.12.e079341.26","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx230"},{"key":"2025121400223048000_13.12.e079341.27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.6078"},{"key":"2025121400223048000_13.12.e079341.28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.2674"},{"key":"2025121400223048000_13.12.e079341.29","doi-asserted-by":"crossref","first-page":"863","DOI":"10.21037\/apm-20-640","article-title":"Overview of prognostic factors in adult gliomas","volume":"10","author":"Sharma","year":"2021","journal-title":"Ann Palliat Med"},{"key":"2025121400223048000_13.12.e079341.30","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S85943"},{"key":"2025121400223048000_13.12.e079341.31","doi-asserted-by":"crossref","first-page":"596","DOI":"10.3389\/fonc.2020.00596","article-title":"Topographical mapping of 436 newly diagnosed IDH Wildtype glioblastoma with vs","volume":"10","author":"Incekara","year":"2020","journal-title":"Front Oncol"},{"key":"2025121400223048000_13.12.e079341.32","doi-asserted-by":"crossref","DOI":"10.1007\/s11864-019-0625-6","article-title":"Controversies in the therapy of low-grade gliomas","volume":"20","author":"Carabenciov","year":"2019","journal-title":"Curr Treat Options Oncol"},{"key":"2025121400223048000_13.12.e079341.33","doi-asserted-by":"crossref","DOI":"10.1007\/s11940-017-0469-y","article-title":"Functional MRI for surgery of gliomas","volume":"19","author":"Castellano","year":"2017","journal-title":"Curr Treat Options Neurol"},{"key":"2025121400223048000_13.12.e079341.34","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/978-3-319-39546-3_45","article-title":"Awake craniotomy for tumor resection: further optimizing therapy of brain tumors","volume":"124","author":"Mehdorn","year":"2017","journal-title":"Acta Neurochir Suppl"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2023-079341","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T08:22:42Z","timestamp":1765700562000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2023-079341"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":34,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12,9]]},"published-print":{"date-parts":[[2023,12]]}},"alternative-id":["10.1136\/bmjopen-2023-079341"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2023-079341","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12]]}}}